Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations. by Bocquier, Aurélie et al.
Dispensing of anxiolytics and hypnotics in southeastern
France: demographic factors and determinants of
geographic variations.
Aure´lie Bocquier, Kamel Bezzou, Steve Nauleau, Pierre Verger
To cite this version:
Aure´lie Bocquier, Kamel Bezzou, Steve Nauleau, Pierre Verger. Dispensing of anxiolytics
and hypnotics in southeastern France: demographic factors and determinants of geographic
variations.. Fundamental & Clinical Pharmacology, 2008, 22 (3), pp.323-33. <10.1111/j.1472-
8206.2008.00587.x>. <inserm-00282216>
HAL Id: inserm-00282216
http://www.hal.inserm.fr/inserm-00282216
Submitted on 2 Jun 2009
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
  
1 
Dispensing of anxiolytics and hypnotics in southeastern France: demographic 
factors and determinants of geographic variations  
Geographic variations in the use of anxiolytics and hypnotics  
 
Aurélie Bocquier1,2, Kamel Bezzou1,2, Steve Nauleau3, Pierre Verger1,2 
1
 Southeastern Health Regional Observatory (ORS PACA) 
2
 French Institute of Health and Medical Research (INSERM UMR 912) 
3
 Southeastern Regional Federation of Health Insurance Funds 
 
Correspondence: 
Aurélie Bocquier, ORS PACA, 23 rue Stanislas Torrents, 13006 Marseilles 
bocquier@marseille.inserm.fr 
telephone: +334 91 59 89 09 / fax number: +334 91 59 89 24 
 
 
The definitive version is available at www.blackwell-synergy.com
H
AL author m
anuscript    inserm
-00282216, version 1
HAL author manuscript
Fundamental & clinical Pharmacology 2008;22(3):323-33
  
2 
Abstract 
Objective. To examine geographic variations in the dispensing of anxiolytics and 
hypnotics (AX-HY) and their determinants at the canton level in southeastern 
France. 
Materials and methods. Data came from the 2005 outpatient database of the 
southeastern France general health insurance fund, covering more than 70% of the 
population. We calculated the annual age-adjusted prevalence rates of subjects 
filling prescriptions for AX-HY at least once (to measure “overall use”) and at 
least six times (“chronic use”), assessed geographic variations with the extremal 
quotient and weighted coefficient of variation, and conducted simple and multiple 
linear regression analysis to study their determinants. 
Results. Prevalence rates of overall and chronic AX-HY use were respectively 
15.5% and 5.9% and varied significantly between cantons, by a factor of 3-4. The 
prevalence of mental illness and that of chronic illness were independently and 
positively associated with overall and chronic use; unemployment rates and mean 
family income were positively associated only with overall use. Density of 
general practitioners did not explain geographic variations. 
Conclusions. These results provide a basis for targeting interventions to reduce 
AX-HY use and promoting appropriate discontinuation. Future studies should 
examine trends in those geographic variations. 
Key words. Psychotropic Drugs, Small-Area Analysis, Socioeconomic Factors, 
Hypnotics and Sedatives, Anti-Anxiety Agents  
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Introduction 
Anxiolytics and hypnotics (AX-HY) are the most commonly used psychotropic 
drugs in Europe in general and especially in France, where the annual prevalence 
rate of its use in 2000 (19%) was nearly double that the average of other European 
countries (10%) [1-3]. In France, these drugs are mainly prescribed by general 
practitioners (GPs) [4] and are often prescribed or used inappropriately: treatment 
often does not match the patient’s actual diagnosis [3], and the length of treatment 
often exceeds recommended durations. Indeed, about 5% of the French population 
uses AX-HY chronically [3, 5]. These reports are particularly worrisome since 
benzodiazepines may cause dependence and side effects [6-11]. 
AX-HY use varies between French administrative regions, ranging from 16% to 
21% for AX and from 8% to 12% for HY [12, 13]. Such geographic differences 
are of concern to policy-makers since they may represent either excessive levels 
of unnecessary care or undertreatment, perhaps due to difficulties in access to 
health services. Priority areas for intervention could be better identified if these 
variations were better described and their determinants more completely 
understood [14-16]. To the best of our knowledge, few studies have focused on 
geographic variations of AX-HY use and its determinants, except for one study in 
France [13] and another in Northern Ireland [17]. The latter showed that 
geographic variations in the prevalence of benzodiazepines use were highly 
associated with the proportions of elderly people and of women in the area [17]. 
Studies of geographic variations in utilization of other mental health services or 
drugs (e.g., acute psychiatric admissions, psychostimulants, antidepressants, and 
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opioid analgesics) suggest that several factors besides demography may explain 
them. Specifically, they include social factors, such as poverty, socioeconomic 
deprivation, social fragmentation, individual isolation, and concentration of 
minority ethnic groups [18-21], as well as the supply and geographic proximity of 
health care services [18, 19, 22]. As far as we know, the prevalence of chronic 
diseases has not been taken into account in previous published articles analysing 
AX-HY use geographic variations, although epidemiological evidence shows 
substantial comorbidity between chronic physical diseases and mental disorders 
[23]. 
In this article, we use the reimbursement database of the southeastern France 
regional health insurance fund (PACA-CNAMTS) to: 1) describe geographic 
variations of the prevalence of AX-HY dispensing at a canton level, and 2) 
identify canton characteristics (demographic and socioeconomic factors, GP 
density, prevalence of chronic illnesses) associated with the prevalence of AX-HY 
dispensing. 
Materials and methods 
Data on dispensing of anxiolytics and hypnotics  
As in other French studies of psychotropic drug use [13, 24, 25], data came from 
the outpatient reimbursement database of the general health insurance fund of 
southeastern France (PACA-CNAMTS). This fund covers salaried employees in 
trade and industry, who account for more than 70% of the population in France as 
a whole and in southeastern France in particular [26]. 
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This database includes all instances in which prescribed drugs were dispensed by 
community pharmacies. It does not include any prescriptions dispensed by public 
hospital pharmacies. Each time a prescribed drug is dispensed by a community 
pharmacy, information on the drug dispensed (barcode) and the patient 
identification number (by means of a "smart" or chip card issued by the health 
insurance authorities) are recorded and electronically sent to the general health 
insurance fund. Pharmacies may not give the patient treatment for more than one 
month at a time. Physicians can prescribe a treatment for a longer duration, if they 
so specify on the prescription. In that case, patient must come back each month to 
the pharmacy with the prescription to get a one-month treatment (prescription 
refills). 
For this study, data included each occasion on which anxiolytics (N05C according 
to the European Pharmaceutical Marketing Research Association  EphMRA  
classification) and nonbarbiturate hypnotics (N05B1-N05B2) were dispensed in 
2005 (Appendix 1). A unique beneficiary identifier that preserves the patient’s 
anonymity linked all events related to the same patient. Data on patients included: 
gender, five-year age group (from 0-4 to 95 years or older), and code of the 
canton of residence. We also knew if subjects were covered by the public 
supplementary health insurance program (“CMUC”) or were exempt from 
copayments because of a long-term illness (the “ALD” program providing 100% 
reimbursement for chronic or long-term disease).  
For each canton, we calculated the 2005 period prevalence of AX-HY dispensing 
as the ratio of individuals with at least one delivery of an AX or HY in 2005 
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(regardless of the location of the pharmacy or of the prescriber) to the number of 
people covered by the general health insurance fund and residing in that canton at 
the end of 2005. We also calculated the prevalence of patients who received an 
AX or HY at least six times, used as a proxy for chronic use [3]. Age-adjusted 
prevalence was calculated for men and women separately with the direct 
standardisation method and with the most recent census data (1999) for the French 
population as the reference (five-year age groups). 
Unit of analysis 
Cantons were chosen as the geographic units for this analysis because they were 
the smallest units for which individual-level health insurance data were available 
that ensured subjects’ anonymity. A French canton is a subdivision of a district 
("département", of which there are 96 in metropolitan France) and is essentially an 
electoral district.  
Southeastern France is divided into 159 cantons. The PACA-CNAMTS database 
included 4,548,171 subjects in 2005. Canton of residence was unknown for 
142,125 subjects (3.1%). The number of subjects per canton ranged from 144 to 
826,901. One canton included fewer than 500 subjects and was not included in the 
canton-level analysis because the expected number of AX-HY users was less than 
five [27]. The regression analysis finally included 4,405,902 subjects from 158 
cantons.  
Explanatory variables 
We defined explanatory variables on the basis of aggregate data at canton level, 
derived from different sources. 
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- Social and demographic data 
Social and demographic data were derived from the 1999 decennial population 
census (from the National Institute of Statistics and Economical Studies, INSEE), 
the most recent available at the canton level. Data included in the analysis were: 
population density (per km²), fraction of the population in four age classes 
(younger than 20 years, 45-59 years, 60-74 years, 75 years or older), and 
percentages of elderly people living alone and of single-parent families. 
- Socioeconomic data 
Also derived from the most recent census were data related to occupational 
category (we noted the proportions of manual workers, office workers, and 
managerial and professional employees), unemployment rate, and proportions of 
subsidized housing, and housing without indoor toilets, bathtubs or showers 
(henceforth referred to as inadequate housing). We also used data on means-tested 
benefits, including income support for people older than 25 years-old (“RMI”) 
and for single-parent families (“API”), and the public supplementary health 
insurance program (“CMUC”), all of which are standard deprivation indicators in 
France; we used the proportion of claimants in each canton in 2001-2002. We 
could calculate the aged-adjusted proportion only for CMUC (in 2005). We also 
included the mean annual family income in 2001 for each canton, provided by the 
tax authorities. 
- General practitioner density 
Rates of GPs per 100,000 persons in 2001 were calculated for each canton based 
on information from the French general health fund database. 
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- Prevalence of chronic illness 
In France, people who suffer from chronic illnesses (e.g., cancer, cardiovascular, 
or respiratory diseases, or diabetes) can be exempted from any copayments for 
medical bills by the “long term-illness” (ALD) program, if their illness is on the 
ALD list. Individual ALD coverage is recorded in the health insurance database. 
We used information from the PACA-CNAMTS database and aged-adjusted rates 
of ALD beneficiaries in each canton in 2005 as an indicator of chronic morbidity 
[28, 29].  
To assess mental illness, we determined age-adjusted proportions of subjects with 
at least one filled prescription for an antipsychotic agent (N05A1-N05A9 
according to the EphMRA classification) in 2005 and used it as a proxy for the 
prevalence of severe mental illness [30, 31]. Antipsychotics are prescribed not 
only for psychotic patients, but also frequently for patients with major depression, 
anxiety, and dementia [32]. Thus the prevalence of antipsychotic use should not 
be interpreted as a proxy for psychotic diseases specifically. 
Statistical analysis 
We calculated descriptive statistics of the variation in the prevalence of AX-HY 
deliveries according to age and gender. We also calculated the Pearson correlation 
coefficient between the global prevalence of AX-HY use and of chronic use. 
At the canton level, all prevalence rates are reported with their 95% confidence 
intervals [33]. These intervals were not calculated at the regional level because the 
numerators and denominators were so high. 
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We measured variation between cantons with the extremal quotient (EQ) and the 
weighted coefficient of variation (COV), two statistics often used in small-area 
analyses [27]. The EQ is the ratio of the highest rate to the lower rate. The 
weighted COV is the ratio of the standard deviation of the rates (among cantons) 
to the mean rate (among cantons) weighted by the population in each canton. We 
compared the calculated values for the EQ and the weighted COV to the estimated 
95th percentile tables generated by Diehr et al. (1990) [27]. 
We analysed age-adjusted prevalence by canton of AX-HY deliveries with simple 
and stepwise multiple linear regression (entry threshold: p<0.20; exit threshold: 
p<0.05) to study its potential determinants separately in men and women. The 
explanatory variables related to population age and density were forced in the 
model. We used the Kolmogorov-Smirnov test to test the normal distribution of 
the dependent variables (threshold: p=0.05) and used the standard “R²” to measure 
the fit of each model (larger values represent a higher percentage of explained 
variance). The statistical analysis used SPSS software (version 14.0; SPSS Inc., 
Chicago, IL). 
Results 
Descriptive results 
Of the 4,406,046 people included in the regional health insurance database, 
684,006 (15.5%) had a prescription for an AX or HY filled at least once in 2005 
(12.6% for AX, and 6.9% for HY); 258,731 (5.9%) had at least six deliveries of 
such drugs in 2005. Prevalence rates increased with age and were higher for 
women than for men (19.8% vs 10.9% for AX and 7.7% vs 3.9% for HY), 
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regardless of age group (Figure 1). Of subjects with at least six deliveries in 2005, 
mean length between two consecutive refills was 34.9 ± 11.3 days. 
Age-adjusted prevalence of AX-HY deliveries varied by canton, from 7.3% [5.6-
9.3] to 25.2% [23.9-26.5] for women (EQ = 3.4; weighted COV = 0.114), and 
from 4.8% [3.4-6.5] to 14.7% [14.1-15.3] for men (EQ = 3.0; weighted 
COV = 0.111). The age-adjusted prevalence of chronic AX-HY use varied from 
2.5% [1.2-4.3] to 9.9% [9.0-10.8] for women (EQ = 3.9; weighted COV = 0.164) 
and from 0.8% [0.1-2.6] to 6.1% [4.2-8.5] (EQ = 8.0; weighted COV = 0.179) for 
men. All EQ and weighted COV values were outside of the 95th percentile values 
estimated by Diehr et al. [27] and thus indicate statistically significant geographic 
variations between cantons (Figure 2).  
All aged-adjusted dispensing rates followed a Gaussian distribution, according to 
the Kolmogorov-Smirnov test. The Pearson correlation coefficient between the 
prevalence of AX-HY deliveries and the prevalence of chronic use was high for 
both men and women (respectively r = 0.753, p < .0001, and r = 0.835, 
p < .0001). 
Factors associated with the prevalence of AX-HY use by cantons 
Among women, the prevalence of subjects with chronic illness and of people 
using antipsychotics, unemployment rates, mean family income, and the 
percentage of subsidized housing were each positively and independently 
associated with the prevalence of AX-HY dispensing (Table I). The results were 
similar for men, except that the significant association with subsidized housing 
rate disappeared (Table II). ‘R²’ was 0.497 for women and 0.533 for men.  
H
AL author m
anuscript    inserm
-00282216, version 1
  
11 
The prevalence of chronic use of AX-HY among women at the canton level was 
strongly and positively associated with the prevalence of antipsychotic use and of 
subjects with chronic illness, the proportion of the population aged 45-59 years, 
and the proportion of subsidized housing. It was negatively associated with the 
proportion of inadequate housing and of the population aged 60-74 years (Table 
I). Among men, it was also positively associated with the prevalence of 
antipsychotic use and of subjects with chronic illnesses, but not with the 
proportion of subsidized housing. As among women, it was also negatively 
associated with the percentage of inadequate housing (Table II). ‘R²’ was 0.518 
for women and 0.474 for men. 
Discussion 
Our results confirm the high prevalence of AX-HY use in southeastern France: 
15.5% of the population had a prescription for AX-HY filled at least once in 2005. 
We cannot rule out the possibility that the true proportion of AX-HY users is 
slightly higher than our results since a small proportion of AX-HY might have 
been delivered without medical prescription. The proportion we found in our 
study is slightly lower than that observed in 2000 from the same source [13]: it 
was then 20.3% for AX and 10.4% for HY. This suggests a decrease in the 
prevalence of AX-HY use, also suggested by the results of the French sample of 
the European Study on the Epidemiology of Mental Disorders (ESEMeD) [3]. The 
introduction in the mid-1990s of new antidepressants, such as selective serotonin 
reuptake inhibitors (SSRIs), may have changed the patterns of psychotropic drug 
prescription. SSRIs may have replaced AX-HY in some cases, especially for the 
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treatment of several anxiety disorders [34], even though the combination of AX-
HY and SSRIs is also common [35, 36].  
Clinical guidelines on the use of anxiolytics and hypnotics were not published in 
France until December 2006 [37, 38], rather late compared with other European 
countries [39-42]. This, in combination with a variety of other factors (such as 
generally high rate of drug demand and use in France, and fee-for-service 
payments), might have contributed to the high prevalence of the use of AX-HY in 
France [43]. 
As previously reported in the literature [44], we observed that use of AX-HY was 
more frequent among women than men. This may result from a higher prevalence 
of depression and anxiety in women [45], gender differences in psychological 
complaints and care-seeking [46], or differences in physicians’ attitudes and 
practices according to patient gender [47, 48]. The prevalence of AX-HY use 
increased substantially with age, and the prevalence of chronic use reached 25% 
among women aged 80 years or older in our study. This result is quite worrisome 
since a recent meta-analysis showed that the benefits of these drugs in people 
older than 60 years may not justify the increased risks [49], which are worsened 
by frequent multiple drug prescriptions in this population. 
Our findings add to existing evidence of significant geographic variations in 
health behaviors and health service utilization. Prevalence of AX-HY use varied 
significantly between cantons, even after we adjusted for age, by a factor on the 
order of three or four (8 for chronic use in men). These variations are consistent 
with those observed for psychostimulant use among children at county and state 
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levels in the USA [20, 50] and antidepressant use in adults at a regional council 
level in New Zealand [51]. 
We found in both sexes that the prevalences of antipsychotic use and chronic 
morbidity at the canton level were the two major independent determinants of the 
rate of AX-HY use, including chronic use. AX-HY are frequently coprescribed 
with antipsychotic drugs, especially among patients with schizophrenia or 
schizoaffective disorders, who often have comorbid psychiatric disorders 
including anxiety disorders and major depression [52, 53]. There is also strong 
evidence of comorbidity between common mental disorders (such as depression 
or anxiety) and other physical health conditions (including coronary heart disease, 
stroke, diabetes, and obesity) even if their interactions are complex: severe 
chronic physical illnesses are associated with an increased risk of mental 
disorders; inversely, mental illnesses can also indirectly increase the risk of 
chronic diseases because they can modify health behaviors (smoking, alcohol use, 
and other health habits, all of which are strong risk factors for disease) and 
treatment compliance [23, 54, 55]. 
Dispensing of AX-HY was highest in cantons where both unemployment and 
mean family income were high and thus suggests strong socioeconomic 
disparities. Explanations for these results may involve individual and 
neighborhood environment factors. Evidence of an association between AX-HY 
use and individual socioeconomic characteristics is contradictory, with some 
studies suggesting negative associations between AX-HY use and education 
levels or income or employment [56-58] while others suggest positive 
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associations with the same characteristics [59, 60]. There is also evidence that 
neighborhood environment affects mental health and thus probably AX-HY use, 
independently of individual socioeconomic factors: the neighborhood 
environment may influence strong determinants of mental health, such as social 
cohesion, stress factors and the resources available to individuals to cope with 
these factors [61, 62]. 
Prevalence of AX-HY use, including chronic use in women, was positively 
associated at the canton level with the proportion of subsidized housing. In 
France, multiple dwelling units, located in urban or peri-urban areas, account for 
most subsidized housing, and one third were constructed in the 1960-70s. More 
than half of all tenants feel their neighborhood is unsafe, and one third of them 
complain about inadequate noise-proofing [63]. These conditions may worsen 
anxiety and sleeplessness and this could lead some people to use AX-HY.  
We also found that prevalence of AX-HY use at the canton level was not 
associated with GP density in the multiple models, contrary to previous studies 
targeting other types of medications (such as psychostimulants and opioid 
antalgics); those reports showed higher rates of use in areas with a high density of 
physicians [22, 50]. The smaller range of GP density in southeastern France  
relatively high and consistent  than in other regions or countries may explain 
this result [64]. This finding also suggests that qualitative aspects of the available 
medical services, more than quantitative elements, need to be taken into account 
in explaining the geographic variations of AX-HY use. Relevant factors may 
include GPs’ personal and professional characteristics and their attitudes and 
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practices, as suggested in other health fields [50, 65, 66]. We are not aware of any 
intervention conducted in southeastern France at canton level to improve 
benzodiazepine prescription. Until recently, GPs were free to take  or not take 
 continuing medical education courses on health topics of their choice. This 
probably contributed to some heterogeneity in prescription practices [36]. 
Finally, the prevalence of chronic AX-HY use in our study was strongly 
associated with the prevalences of antipsychotic use and chronic morbidity. 
Contrary to overall use prevalence, it was not associated with unemployment rates 
or income levels. This is consistent with previous results showing that factors 
associated with long-term use of AX-HY differ from those associated with any 
use [59]. Age, disability, and mental and somatic illnesses appear to be the 
strongest determinants of chronic benzodiazepine use [67-69]. 
Like other studies analyzing pharmaceutical reimbursement data, our study has 
some limitations. It is based on the database of the French general health 
insurance fund, which does not cover farmers, tradespeople, shopkeepers, 
professional occupations and other self-employed workers. As far as we know, 
little information is available on psychotropic drug use in these groups. One study 
observed a higher annual prevalence of AX-HY use among general practitioners 
 classified as self-employed workers  than in the general population [70]. 
However, evidence on the association between AX-HY use and socioeconomic 
groups remains still contradictory [56-60]. Consequently, our results cannot be 
considered as representative of the regional population as a whole. 
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The database does not include reimbursements for drugs dispensed by public 
hospitals. A study of 91 hospitalized patients showed that 46% of them had been 
prescribed an AX or HY during their hospitalization [71]. GPs often, however, 
continue AX or HY treatment initially prescribed in hospitals. 
Moreover, data from the health fund database do not provide information about 
the medical reasons for prescriptions, or about whether purchasers take the drugs 
as prescribed or at all.  
Finally, in this study, sociodemographic characteristics and GP density were 
derived from data corresponding to calendar years different from that for AX-HY 
deliveries (respectively 1999, 2001 and 2005). Data available on unemployment 
rate and GP density at different geographic levels suggest that differences 
between cantons did not vary substantially during the period 1999-2005 however 
[72, 73].  
Conclusion 
Our study showed that the prevalence of AX-HY use in the general population in 
southeastern France exceeds 15%. The finding that more than one third of 
consumers use AX-HY chronically is disquieting in view of the side effects of 
benzodiazepines. Our results revealed variation on the order of 3-4 in the 
prevalence of AX-HY dispensing at the canton level. Differences in the 
prevalence of mental and chronic illness were the major determinants of these 
geographic variations of AX-HY use in southeastern France, especially for 
chronic use. Moreover, we found that overall prevalence of AX-HY use was 
higher in cantons where both unemployment and mean family income were high. 
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These results provide a basis for public health decision-makers. In particular, they 
may help them to set priorities in targeting a variety of interventions. These might 
include better information to the local general population and health care 
professionals about the side effects of benzodiazepines and therapeutic 
alternatives to them, to reduce the number of new AX-HY treatments and thus the 
risk of dependence. Continuing medical education for GPs should also include the 
guidelines for stopping AX-HY treatment. Future studies are needed to examine 
trends in geographic variations in the use of AX-HY, better disentangle their 
individual and contextual determinants and evaluate public health action in this 
field. 
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Table I: Determinants of the prevalence of overall and chronic AX-HY use among 
women at the canton level (n=158). Southeastern France general health 
fund, 2005 
 
AX-HY dispensed at least once Chronic use of AX-HY 
  
Simple 
regression 
Multiple 
regressiona 
Simple 
regression 
Multiple 
regressiona 
 
        
Social and demographic characteristics 
  
 
  
Population density  1.10 *** -0.00  0.44 ** 0.05 
% <20 years 0.18 *  0.01  0.03  -0.05  
% 45-59 years 0.11   0.08  0.03  0.08 * 
% 60-74 years -0.02  -0.03  -0.01  -0.07 * 
% >75 years -0.13   0.01  0.00  0.05  
% elderly living alone 0.01    0.01    
% single-parent families 0.13 *   0.06 *   
 
 
 
 
 
 
 
 
 
Socioeconomic characteristics         
% manual workers 0.09 *   0.06 **   
% office workers 0.12 *   0.05 *   
% managerial and professional employees 0.19 **   0.03    
Unemployment rate 0.27 ***  0.16 ** 0.10 ***   
Mean annual income per family 0.21 *  0.35 *** -0.02    
% “RMI” recipients 0.60 ***    0.23 ***   
% “API” recipients 0.06     0.05 **   
Aged-adjusted % “CMUC” recipients 0.44 ***    0.20 ***   
% inadequate housing -0.88 ***   -0.30 ** -0.37 *** 
% subsidized housing 0.18 ***  0.10 ***  0.08 *** 0.04 ** 
 
 
 
 
 
 
 
 
 
Availability of health services          
Rate of FPs 1.92     2.64    
 
 
 
 
 
 
 
 
 
Prevalence of chronic illness         
Aged-adjusted % “ALD” recipients 0.61 ***  0.36 **  0.40 *** 0.25 *** 
Aged-adjusted % of users of antipsychotics  2.05 ***  1.24 **  1.13 *** 0.65 *** 
 
 
 R² = 0.497   R² = 0.518 
 
  
 
 
a Adjusted for population age and density    
* p<.05     
** p<.01     
*** p<.001     
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Table II: Determinants of the prevalence of overall and chronic AX-HY use 
among men at canton-level (n=158). Southeastern France general health fund, 
2005 
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*** 
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Figure 1: Proportion of subjects with AX-HY prescriptions filled either once or at 
least six times, according to gender and age. Southeastern France general health 
fund, 2005 
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Figure 2: Age-adjusted prevalence of AX-HY use at canton-level (%) 
(Southeastern France general health fund, 2005), and population (INSEE, census 
1999) 
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Appendix 1: List of anxiolytics and nonbarbiturate hypnotics included in the study 
according to their proprietary (brand) name 
Anxiolytics  Nonbarbiturate hypnotics 
ALPRAZOLAM ARROW (0.25 MG, 0.50 MG)  FLUNITRAZEPAM RPG (1 MG)            
ALPRAZOLAM BIOGARAN (0.25 MG, 0.50 MG)  HALCION (0.125 MG)                
ALPRAZOLAM EG (0.25 MG, 0.50 MG)  HAVLANE (1 MG)                
ALPRAZOLAM G GAM (0.25 MG, 0.50 MG)        IMOVANE (3.75 MG, 7.5 MG)                     
ALPRAZOLAM GNR (0.25 MG, 0.50 MG)        MEPRONIZINE                             
ALPRAZOLAM IREX (0.25 MG, 0.50 MG)          MOGADON (5 MG)            
ALPRAZOLAM MERCK (0.25 MG, 0.50 MG)                     NOCTAMIDE (1 MG, 2 MG)                         
ALPRAZOLAM RATIOPHARM (0.25 MG, 0.50 MG)           NOCTRAN                      
ALPRAZOLAM RPG  (0.25 MG, 0.50 MG)                      NORMISON (10 MG, 20 MG)                            
ALPRAZOLAM SANDOZ (0.25 MG, 0.50 MG)                        NUCTALON (2 MG)                  
ALPRAZOLAM TEVA (0.25 MG, 0.50 MG)          ROHYPNOL (1 MG)                    
ALPRAZOLAM WINTHROP (0.25 MG, 0.50 MG)               STILNOX (10 MG)                   
ALPRAZOLAM ZYDUS (0.25 MG, 0.50 MG)                       ZOLPIDEM ARROW (10 MG) 
ANXYREX (6 MG)                       ZOLPIDEM BIOGARAN (10 MG)             
ATARAX (100 MG)                      ZOLPIDEM EG (10 MG)                    
ATARAX (100 MG/2 ML)                    ZOLPIDEM G GAM (10 MG)                           
ATARAX (25 MG)                           ZOLPIDEM GNR (10 MG)                           
ATARAX SIROP (1/200 ML)                             ZOLPIDEM IREX (10 MG)                     
BROMAZEPAM ARROW (6 MG)                       ZOLPIDEM IVAX (10 MG)                       
BROMAZEPAM BIOGARAN (6 MG)                     ZOLPIDEM MERCK (10 MG)                         
BROMAZEPAM EG (6 MG)                           ZOLPIDEM QUALIMED (10 MG)                   
BROMAZEPAM G GAM (6 MG)                        ZOLPIDEM RATIOPHARM (10 MG)           
BROMAZEPAM GNR (6 MG)                          ZOLPIDEM RPG (10 MG)                           
BROMAZEPAM IREX (6 MG)                        ZOLPIDEM SANDOZ (10 MG)                         
BROMAZEPAM IVAX (6 MG)                          ZOLPIDEM TEVA (10 MG)                       
BROMAZEPAM MERCK (6 MG)                        ZOLPIDEM WINTHROP (10 MG)                  
BROMAZEPAM QUALIMED (6 MG)                     ZOLPIDEM ZYDUS (10 MG)                  
BROMAZEPAM RATIOPHARM (6 MG)                  ZOPICLONE ARROW (7.5 MG)                
BROMAZEPAM RPG (3 MG)                        ZOPICLONE BIOGARAN (7.5 MG)                
BROMAZEPAM RPG (6 MG)                         ZOPICLONE EG (7.5 MG)                        
BROMAZEPAM TEVA (6 MG)                       ZOPICLONE G GAM (7.5 MG)                     
BROMAZEPAM WINTHROP (6 MG)                     ZOPICLONE GNR (7.5 MG)                       
BROMAZEPAM ZYDUS (6 MG)                       ZOPICLONE IREX (7.5 MG)                      
BUSPAR (10 MG)                                 ZOPICLONE IVAX (7.5 MG)                         
BUSPIRONE G GAM (10 MG)                        ZOPICLONE MERCK (7.5 MG)                     
BUSPIRONE MERCK (10 MG)                         ZOPICLONE QUALIMED (7.5 MG)                      
COVATINE (50 MG)                           ZOPICLONE RATIOPHARM (7.5 MG)           
DIAZEPAM RATIOPHARM (2 MG, 5 MG, 10 MG)                     ZOPICLONE RPG (7.5 MG)                       
EQUANIL (250 MG, 400 MG)                             ZOPICLONE SANDOZ (7.5 MG)                         
EQUANIL (400 MG/5 ML)                ZOPICLONE TEVA (7.5 MG)                        
LEXOMIL 6 MG                   ZOPICLONE WINTHROP (7.5 MG)            
LORAZEPAM MERCK (1 MG, 2.5 MG)                        ZOPICLONE ZYDUS (7.5 MG)                      
LYSANXIA (10 MG)                             
LYSANXIA (15 MG/ML)                 
MEPROBAMATE RICHARD (200 MG)                    
NORDAZ (7.5 MG, 15 MG)                                  
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NOVALM (400 MG)                                 
NOVAZAM (10 MG)                             
QUIETILINE (6 MG)                  
SERESTA (10 MG, 50 MG)                                 
TEMESTA (1 MG, 2.5 MG)                                  
TRANXENE (5 MG, 10 MG, 20 MG, 50 MG)    
TRANXENE (20 MG/2 ML)   
TRANXENE (50 MG/2.5 ML)   
URBANYL (5 MG, 10 MG, 20 MG)                        
VALIUM ROCHE (2 MG, 5 MG, 10 MG)                            
VALIUM ROCHE (10 MG/2 ML SOL INJ)                 
VALIUM ROCHE (10 MG/ML SOL BUV)       
VERATRAN (5 MG, 10 MG)                                 
VICTAN (2 MG)                     
XANAX (0.25 MG, 0.50 MG)                                
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